Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Veradigm ( (MDRX) ) is now available.
On February 2, 2026, Veradigm’s board approved a further extension of the company’s Stockholder Rights Plan, pushing its expiration to December 31, 2026, and maintaining a 20% ownership threshold at which the rights become exercisable for any investor or group whose acquisition of common stock is not approved by the board. The move, which follows a series of amendments since the plan’s original adoption in February 2024, is intended to protect shareholders while the company works to resolve delayed financial reporting and pursue relisting on a national stock exchange, underscoring ongoing governance and reporting challenges that remain material for investors.
The most recent analyst rating on (MDRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Veradigm stock, see the MDRX Stock Forecast page.
More about Veradigm
Veradigm, traded over the counter under the ticker MDRX, is a healthcare technology company that provides clinical and revenue cycle management solutions primarily to independent medical practices. Leveraging AI-driven data and technology, it connects more than 20,000 provider practices with health plans and biopharmaceutical companies to reduce inefficiencies, close care gaps, and support a more cost-effective healthcare system.
Average Trading Volume: 238,845
Technical Sentiment Signal: Strong Sell
Current Market Cap: $518.4M
See more data about MDRX stock on TipRanks’ Stock Analysis page.